Previous 10 | Next 10 |
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2022,...
The stock may be down by 60% over the past 12 months, but Maravai LifeSciences Holdings (NASDAQ: MRVI) is still in Wall Street's good graces, with all 10 of the big-time financial analysts who cover the stock rating it as either a buy or a strong buy. In the face of such a steep dec...
Summary The market is greatly overestimating the effect of higher rates and inflation on durable goods, materials and financial companies, while underestimating the impact on speculative assets. The Strategy underperformed its Russell 2000 benchmark, as positive contributions from...
Summary Maravai has seen a real boom from the pandemic. Sales could likely see pressure in 2023, even as underlying non-pandemic related growth seems solid. I like the set-up here, even as the near to medium term will likely see some negative year-over-year sales declines, lik...
Executive Chairman and former CEO of Maravai LifeSciences ( NASDAQ: MRVI ), Carl Hull, has been reinstated as CEO of the company on an interim basis. Three subsidiaries of Danaher, two of which previously employed recently-appointed Maravai CEO William “Trey...
SAN DIEGO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Executive Chairman and former CEO of Maravai LifeSciences, Inc. (NASDAQ: MRVI) Carl Hull, has been reinstated as CEO of the company on an interim basis. Three subsidiaries of Danaher Corporation, two of which previously employed recently-...
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2022 financial and operating results after the market clos...
Maravai LifeSciences ( NASDAQ: MRVI ) on Monday said it had appointed William Martin, III as its CEO, succeeding co-founder Carl Hull. Martin joins MRVI from Danaher ( DHR ) where he was the senior vice president of new business, genomic medicine. Hull will remain ...
William “Trey” Martin, III appointed to succeed Carl Hull as Chief Executive Officer Hull to Serve as Executive Chairman of the Board of Directors SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life ...
SAN DIEGO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (Maravai) (NASDAQ: MRVI) and global provider of life science reagents and services, has expanded its GMP-grade product offering to include N1-Methyl-Pseudouridine-5’-Tr...
News, Short Squeeze, Breakout and More Instantly...
Maravai LifeSciences Holdings Inc. Company Name:
MRVI Stock Symbol:
NASDAQ Market:
Maravai LifeSciences Holdings Inc. Website:
2024-07-25 20:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on...
- Highlights progress across four priority areas and commitment to environmentally and socially responsible growth. - Conducted first stakeholder assessment to identify and prioritize ESG issues that are most important for Maravai and our stakeholders. - Increased the sc...